Effectiveness and safety of pharmacological treatments for Cushing's disease: An updated systematic review and meta-analysis.
Pasireotide has a disease control rate of 42% in Cushing's disease, but clinicians should be cautious due to the very low certainty of evidence and the risk of dysglycemia.
Where it sits
this study against the rest of the pasireotide corpusSummary and findings
This systematic review assessed the efficacy and safety of pharmacological treatments for Cushing's disease, including pasireotide, in a population of 580 patients across 10 studies. The disease control rate for pasireotide was reported as 42%. The study also highlighted adverse events associated with the treatments, particularly dysglycemia linked to pasireotide.
Abstract
<h4>Objective</h4>To provide an updated assessment of the efficacy, safety, and clinical outcomes of pharmacological treatments for Cushing's disease, focusing on cabergoline, ketoconazole, pasireotide, and osilodrostat.<h4>Materials and methods</h4>This systematic review update was conducted using the Joanna Briggs Institute methodology. Outcomes included disease control rates, adverse events, and improvements in comorbidities and quality of life.<h4>Results</h4>Eleven new studies were included. In the updated analysis, disease control rates were 35.5% for cabergoline (95% confidence interval [CI]: 28-43%; 7 studies, 155 patients), 42% for ketoconazole (95% CI: 38-47%; 7 studies, 488 patients), 42% for pasireotide (95% CI: 28-58%; 10 studies, 580 patients), and 67% for osilodrostat (95% CI: 61-73%; 4 studies, 263 participants). According to GRADE, certainty of evidence was very low for pasireotide and low for the other agents. Osilodrostat increased cortisol normalization 4.56-fold versus placebo (95% CI: 1.53-13.56; 2 studies, 144 patients; moderate certainty). Osilodrostat and pasireotide improved CushingQoL scores by 13.23 points (95% CI: 10.78-15.68) and 8.96 points (95% CI: 4.37-13.55), respectively. Pasireotide was predominantly associated with dysglycemia. Cabergoline most often caused mild adverse events, with treatment escape in 11%. Ketoconazole was linked to mildly elevated transaminases and gastrointestinal symptoms. Osilodrostat most commonly resulted in fatigue and adrenal insufficiency, often reflecting therapeutic response.<h4>Conclusion</h4>Pharmacological disease control rates in Cushing's disease range from 35.5% to 67%, with osilodrostat achieving the highest rates and being the only agent supported by placebo-controlled evidence demonstrating a statistically significant effect. In the absence of head-to-head comparisons, treatment decisions remain individualized.
Background
This paper addresses the effectiveness and safety of pharmacological treatments for Cushing's disease, a condition characterized by excess cortisol. Prior studies have indicated varying efficacy among treatments, but this review aims to provide a comprehensive update on recent findings. Understanding the comparative effectiveness of these agents is crucial for guiding clinical decisions.
Methods
The study utilized the Joanna Briggs Institute methodology for systematic review. It included 11 new studies focusing on disease control rates, adverse events, and improvements in comorbidities and quality of life. The population included patients with Cushing's disease treated with various pharmacological agents.
Results
The primary endpoint for pasireotide showed a disease control rate of 42% (95% CI: 28-58%; 10 studies, 580 patients). Osilodrostat demonstrated a higher disease control rate of 67% (95% CI: 61-73%; 4 studies, 263 participants). Improvements in CushingQoL scores were reported as 8.96 points for pasireotide (95% CI: 4.37-13.55).
Interpretation
While pasireotide demonstrated a disease control rate of 42%, the evidence quality was rated very low, indicating uncertainty in its effectiveness. Compared to osilodrostat, which had a higher disease control rate and moderate certainty evidence, the clinical significance of pasireotide's effect may be limited. The findings suggest that treatment choices should be individualized, taking into account the varying levels of evidence and potential adverse effects.
Key findings
- Disease control rate of 42% for pasireotide (95% CI: 28-58%; 10 studies, 580 patients)
- Osilodrostat achieved a disease control rate of 67% (95% CI: 61-73%; 4 studies, 263 participants)
- CushingQoL scores improved by 8.96 points for pasireotide (95% CI: 4.37-13.55)
- Osilodrostat increased cortisol normalization 4.56-fold versus placebo (95% CI: 1.53-13.56; 2 studies, 144 patients)
- Certainty of evidence for pasireotide was rated as very low according to GRADE
Limitations
- Certainty of evidence for pasireotide rated as very low
- No head-to-head comparisons available
- Adverse events predominantly included dysglycemia
- Study included multiple pharmacological agents without direct comparisons